GlycoMimetics Inc.

2.02-0.0200-0.98%Vol 310.40K1Y Perf -56.18%
Jul 27th, 2021 15:03 DELAYED
BID2.02 ASK2.03
Open2.04 Previous Close2.04
Pre-Market2.08 After-Market-
 0.04 1.96%  - -
Target Price
10.67 
Analyst Rating
Strong Buy 1.40
Potential %
428.22 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★★+     57.70
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap104.11M 
Earnings Rating
Buy
Price Range Ratio 52W %
2.25 
Earnings Date
30th Jul 2021

Today's Price Range

1.992.05

52W Range

1.964.63

5 Year PE Ratio Range

-7.20-4.10

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-1.92%
1 Month
-18.73%
3 Months
-21.24%
6 Months
-46.17%
1 Year
-56.18%
3 Years
-85.27%
5 Years
-76.00%
10 Years
-

TickerPriceChg.Chg.%
GLYC2.02-0.0200-0.98
AAPL147.26-1.7300-1.16
GOOG2 734.85-58.0400-2.08
MSFT286.32-2.7300-0.94
XOM57.79-0.6900-1.18
WFC45.090.08000.18
JNJ172.340.47000.27
FB367.03-5.4300-1.46
GE13.130.21001.63
JPM151.55-0.1000-0.07
Financial StrengthValueIndustryS&P 500US Markets
12.30
12.30
0.01
0.02
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-2 600.10
-2 587.90
-
-
RevenueValueIndustryS&P 500US Markets
2.22M
0.04
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.32-0.2812.50
Q04 2020-0.32-0.320.00
Q03 2020-0.33-0.2912.12
Q02 2020-0.37-0.3213.51
Q01 2020-0.30-0.1840.00
Q04 2019-0.35-0.342.86
Q03 2019-0.39-0.3120.51
Q02 2019-0.36-0.37-2.78
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.310.00-
9/2021 QR-0.310.00-
12/2021 FY-1.261.56Positive
12/2022 FY-1.362.86Positive
Next Report Date30th Jul 2021
Estimated EPS Next Report-0.31
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume310.40K
Shares Outstanding51.54M
Trades Count1.76K
Dollar Volume3.67M
Avg. Volume785.29K
Avg. Weekly Volume256.93K
Avg. Monthly Volume397.78K
Avg. Quarterly Volume736.77K

GlycoMimetics Inc. (NASDAQ: GLYC) stock closed at 2.04 per share at the end of the most recent trading day (a -3.32% change compared to the prior day closing price) with a volume of 378.26K shares and market capitalization of 104.11M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 57 people. GlycoMimetics Inc. CEO is Rachel K. King.

The one-year performance of GlycoMimetics Inc. stock is -56.18%, while year-to-date (YTD) performance is -45.74%. GLYC stock has a five-year performance of -76%. Its 52-week range is between 1.96 and 4.63, which gives GLYC stock a 52-week price range ratio of 2.25%

GlycoMimetics Inc. currently has a PE ratio of -1.70, a price-to-book (PB) ratio of 0.87, a price-to-sale (PS) ratio of 49.02, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.13%, a ROC of -41.25% and a ROE of -40.72%. The company’s profit margin is -%, its EBITDA margin is -2 587.90%, and its revenue ttm is $2.22 Million , which makes it $0.04 revenue per share.

Of the last four earnings reports from GlycoMimetics Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.31 for the next earnings report. GlycoMimetics Inc.’s next earnings report date is 30th Jul 2021.

The consensus rating of Wall Street analysts for GlycoMimetics Inc. is Strong Buy (1.4), with a target price of $10.67, which is +428.22% compared to the current price. The earnings rating for GlycoMimetics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

GlycoMimetics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

GlycoMimetics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 20.46, ATR14 : 0.11, CCI20 : -73.59, Chaikin Money Flow : -0.16, MACD : -0.09, Money Flow Index : 24.54, ROC : -5.56, RSI : 36.42, STOCH (14,3) : 23.53, STOCH RSI : 0.39, UO : 48.68, Williams %R : -76.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of GlycoMimetics Inc. in the last 12-months were: Brian M. Hahn (Option Excercise at a value of $5 891), Rachel K. King (Option Excercise at a value of $146 520), Rachel K. King (Sold 84 176 shares of value $329 128 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (66.67 %)
4 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (20.00 %)
2 (33.33 %)
2 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Moderate Buy
1.67
Moderate Buy
1.67

GlycoMimetics Inc.

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.

CEO: Rachel K. King

Telephone: +1 240 243-1201

Address: 9708 Medical Center Drive, Rockville 20850, MD, US

Number of employees: 57

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

48%52%

News

Stocktwits